6.
Unsicker K, Flanders K, Cissel D, Lafyatis R, Sporn M
. Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neuroscience. 1991; 44(3):613-25.
DOI: 10.1016/0306-4522(91)90082-y.
View
7.
Meijering E, Jacob M, Sarria J, Steiner P, Hirling H, Unser M
. Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A. 2004; 58(2):167-76.
DOI: 10.1002/cyto.a.20022.
View
8.
Peters S, Zitzelsperger E, Kuespert S, Iberl S, Heydn R, Johannesen S
. The TGF-β System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis. Front Neurol. 2018; 8:669.
PMC: 5736544.
DOI: 10.3389/fneur.2017.00669.
View
9.
Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A
. Recent advances in amyotrophic lateral sclerosis. J Neurol. 2016; 263(6):1241-54.
PMC: 4893385.
DOI: 10.1007/s00415-016-8091-6.
View
10.
Vincze C, Pal G, Wappler E, Szabo E, Nagy Z, Lovas G
. Distribution of mRNAs encoding transforming growth factors-beta1, -2, and -3 in the intact rat brain and after experimentally induced focal ischemia. J Comp Neurol. 2010; 518(18):3752-70.
DOI: 10.1002/cne.22422.
View
11.
David C, Massague J
. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018; 19(7):419-435.
PMC: 7457231.
DOI: 10.1038/s41580-018-0007-0.
View
12.
Houi K, Kobayashi T, Kato S, Mochio S, Inoue K
. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2002; 106(5):299-301.
DOI: 10.1034/j.1600-0404.2002.01301.x.
View
13.
Feldman E, Goutman S, Petri S, Mazzini L, Savelieff M, Shaw P
. Amyotrophic lateral sclerosis. Lancet. 2022; 400(10360):1363-1380.
PMC: 10089700.
DOI: 10.1016/S0140-6736(22)01272-7.
View
14.
Fang T, Al Khleifat A, Meurgey J, Jones A, Leigh P, Bensimon G
. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018; 17(5):416-422.
PMC: 5899963.
DOI: 10.1016/S1474-4422(18)30054-1.
View
15.
Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R
. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol Neurodegener. 2018; 13(1):60.
PMC: 6223075.
DOI: 10.1186/s13024-018-0292-2.
View
16.
Bandmann O, Burton E
. Genetic zebrafish models of neurodegenerative diseases. Neurobiol Dis. 2010; 40(1):58-65.
DOI: 10.1016/j.nbd.2010.05.017.
View
17.
Oliveira N, Pinho B, Oliveira J
. Swimming against ALS: How to model disease in zebrafish for pathophysiological and behavioral studies. Neurosci Biobehav Rev. 2023; 148:105138.
DOI: 10.1016/j.neubiorev.2023.105138.
View
18.
Mancuso R, Navarro X
. Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Prog Neurobiol. 2015; 133:1-26.
DOI: 10.1016/j.pneurobio.2015.07.004.
View
19.
Shefner J, Heiman-Patterson T, Pioro E, Wiedau-Pazos M, Liu S, Zhang J
. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve. 2019; 61(2):218-221.
PMC: 7004197.
DOI: 10.1002/mus.26740.
View
20.
Peng D, Fu M, Wang M, Wei Y, Wei X
. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022; 21(1):104.
PMC: 9033932.
DOI: 10.1186/s12943-022-01569-x.
View